Search

Displaying results 3431 - 3440 of 10000 in total
  1. Drug

    Maxy-G34

    go.drugbank.com/drugs/DB05718
    Investigational

    , while Neulasta has a single 20 Kd PEG group attached at the N terminal end of the wild type G-CSF protein. … Specifically, the amino acid sequence of MAXY-G34 differs from that of human wild type G-CSF at residues 16, 34, 40, 105 and 159.

  2. Drug

    Turpentine

    go.drugbank.com/drugs/DB11120
    Approved

    It is used as a solvent and base material in organic synthesis reactions.

    Mixtures: Cal Mo Dol Ont, BUĞUMENTOL BUĞU, 40 G
  3. Drug

    Enristomig

    go.drugbank.com/drugs/DB29060
    Investigational

    INBRX-105 is a biologic drug. … INBRX-105 is under investigation in clinical trial NCT03809624 (Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer).

  4. Drug

    Pegunigalsidase alfa

    go.drugbank.com/drugs/DB14992
    ApprovedInvestigational

    Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized … [A259347,A259352] In May 2023, the EMA granted marketing authorization to pegunigalsidase alfa in the European Union (EU) for the treatment of adult patients with Fabry disease.

  5. Drug

    CNDO-109

    go.drugbank.com/drugs/DB17290
    Investigational

    CNDO-109 are CNDO-109-activated allogeneic natural killer cells.

    Synonyms: CNDO-109-NK, CNDO-109-AANK Cells
  6. Drug

    Homatropine

    go.drugbank.com/drugs/DB11181
    Approved

    Homatropine is an anticholinergic drug that acts as an antagonist at muscarinic acetylcholine receptors. … administered as ophthalmic solutions as a cycloplegic to temporarily paralyze accomodation, and to induce mydriasis (the dilation of the pupil); however such therapeutic use has not been approved by the FDA to be

  7. Drug

    Ascorbyl phosphate

    go.drugbank.com/drugs/DB11352
    ApprovedInvestigational

    These salts are present in cosmetic products at concentrations ranging from 0.001 % to 3% [A27211].

    Mixtures: Le-Blen Vitamin C Serum
  8. Drug

    Moxidectin

    go.drugbank.com/drugs/DB11431
    ApprovedInvestigationalVet approved

    Moxidectin differs by the absence of a disaccharide moiety on carbon 13, a substituted olefinic side chain at carbon 25 and a unique methoxime moiety at carbon 23. … It was first used in cattle followed by an approved use in general animals. It is a semi-synthetic methoxine derivative of nemadectin which is a 16-member pentacyclic lactone of the milbemycin class.

  9. Drug

    Lucinactant

    go.drugbank.com/drugs/DB04897
    Approved

    It is completely devoid of animal-derived components. FDA approved on March 6, 2012. … More specifically, it mimics the C-terminal amphipathic helical domain of this protein.

  10. Drug

    Alvespimycin

    go.drugbank.com/drugs/DB12442
    Investigational

    It has been used in trials studying the treatment of solid tumor in various cancer as an antitumor agent. … In comparison to the first HSP90 inhibitor tanespimycin, it exhibits some pharmacologically desirable properties such as reduced metabolic liability, lower plasma protein binding, increased water solubility